Wolfe Research downgraded Axonics (AXNX) to Peer Perform from Outperform without a price target. The analyst sees the proposed cash acquisition price of $71 per share from Boston Scientific (BSX) as a fair valuation and great outcome for Axonics shareholders. The firm expects there to be “de minimis friction” delivering the planned first half of 2024 close.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXNX:
- M & A News: Boston Scientific (NYSE:BSX) to Acquire Axonics in $3.7B Deal
- Boston Scientific Announces Agreement to Acquire Axonics, Inc.
- 5 Top MedTech Stocks for 2024, According to Analysts from Baird
- Axonics price target raised to $73 from $65 at Truist
- NeuroPace price target raised to $8 from $6 at Morgan Stanley
